The effects of serum-derived bovine immunoglobulin/protein isolate (SBI) will be evaluated and compared to matching placebo in two distinct patient populations:~I. Hospitalized ulcerative colitis (UC) patients who tested positive for Clostridium difficile (C. difficile) at time of admission and are receiving vancomycin.~Primary Objective:~• To evaluate the effect of SBI on time (# of days) to resolution of diarrhea, defined as a consecutive 24 hour period with only formed bowel movements (Bristol Stool Scale (BSS) ≤ 4) in this patient population~Secondary Objectives:~To evaluate the ability of SBI to decrease the incidence of recurrent C. difficile infection (CDI) following successful treatment with vancomycin.~To evaluate the effect of SBI on UC status~To evaluate the effect of SBI on nutritional status~To evaluate the safety and tolerability of SBI~To evaluate the effect of SBI on subjects' quality of life (QOL)~To investigate the effect of SBI in fecal microbiome~To evaluate the length of hospitalization (time of hospitalization to time of discharge)~II. Hospitalized UC patients who tested negative for C. difficile at time of admission.~Primary Objective:~• To evaluate the effect of SBI on time (# of days) to resolution of diarrhea, defined as a consecutive 24 hour period with only formed bowel movements (Bristol Stool Scale (BSS) ≤ 4) in this patient population~Secondary Objectives:~To evaluate the effect of SBI in decreasing the incidence of CDI~To evaluate the effect of SBI on UC status~To evaluate the effect of SBI on nutritional status~To evaluate the safety and tolerability of SBI~To evaluate the effect of SBI on subjects' QOL~To investigate the effect of SBI in fecal microbiome~To evaluate the length of hospitalization (time of hospitalization to time of discharge)
The effects of serum-derived bovine immunoglobulin/protein isolate (SBI) will be evaluated and compared to matching placebo in two distinct patient populations:~I. Hospitalized ulcerative colitis (UC) patients who tested positive for Clostridium difficile (C. difficile) at time of admission and are receiving vancomycin.~II. Hospitalized UC patients who tested negative for C. difficile at time of admission.